Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Understanding hair growth involves complex factors, and more research is needed to improve treatments for hair loss conditions.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

miR-199a-3p controls hair growth and is linked to alopecia areata.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

A patient experienced severe hair loss after getting an mRNA COVID-19 vaccine.

Certain skin symptoms in COVID-19 patients may indicate a more severe illness.

COVID-19 has widely affected health, various industries, and the economy, but also led to more remote work and less pollution.

Alopecia areata in children is usually mild and effectively treated with strong topical steroids.

New treatments focusing on immune pathways show promise for stubborn hair loss.

COVID-19 vaccines do not increase the risk of alopecia areata.

Regenerative medicine is effective and safe for treating vitiligo.

Hydrangea serrata extract may promote hair growth and improve hair health.

Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.

Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Low-dose oral minoxidil is safe for treating children's hair disorders.

Tofacitinib is an effective and safe treatment for alopecia areata.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Effective treatment guidelines for frontal fibrosing alopecia are still unclear.

Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.

LC-OCT is a promising tool for diagnosing and monitoring Alopecia areata.

Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.

Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.